Market closedNon-fractional

C4 Therapeutics/CCCC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About C4 Therapeutics

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

Ticker

CCCC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Watertown, United States

Employees

145

C4 Therapeutics Metrics

BasicAdvanced
$311M
Market cap
-
P/E ratio
-$2.31
EPS
3.11
Beta
-
Dividend rate
$311M
3.11
5.082
4.94
24.92
26.994
-172.86%
-20.86%
-48.42%
12.293
1.2
1.2
-2.65
-26.34%
-13.79%
-16.00%
-11.74%

What the Analysts think about C4 Therapeutics

Analyst Ratings

Majority rating from 8 analysts.
Buy

C4 Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-943.33% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3M
-6.25%
Net income
-$28M
-18.44%
Profit margin
-943.33%
-13.01%

C4 Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 16.67%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.73
-$0.55
-$0.70
-$0.41
-
Expected
-$0.69
-$0.66
-$0.68
-$0.35
-$0.37
Surprise
6.14%
-16.67%
2.56%
16.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for C4 Therapeutics stock?

C4 Therapeutics (CCCC) has a market cap of $311M as of July 06, 2024.

What is the P/E ratio for C4 Therapeutics stock?

The price to earnings (P/E) ratio for C4 Therapeutics (CCCC) stock is 0 as of July 06, 2024.

Does C4 Therapeutics stock pay dividends?

No, C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next C4 Therapeutics dividend payment date?

C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders.

What is the beta indicator for C4 Therapeutics?

C4 Therapeutics (CCCC) has a beta rating of 3.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell C4 Therapeutics stock

Buy or sell C4 Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing